Luvometinib vs Trametinib
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: MEK1/2 · full Non-Small Cell Lung Cancer pipeline
Luvometinib
Marketed by Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: June 2029 · NCT07562581 (registry estimate)
No aligned efficacy figure on record for this race.
Trametinib
Marketed by Novartis and partners
NCT01362296 · Phase 2 · completed
This was a randomized, active-controlled trial against a standard chemotherapy comparator, but it was conducted without blinding, and the primary progression-free-survival endpoint was not statistically different between arms (hazard ratio 1.14, 95% CI 0.75 to 1.75, p=0.5197).
Next expected readout: July 2027 · NCT03333343 (registry estimate)
Reported efficacy
Overall Response Rate (ORR) (From study treatment start date until first documented complete response or partial response, assessed up to approximately 50 months): Overall Response Rate (ORR) (From study treatment start date until first documented complete response or partial response, assessed up to approximately 50 months): Cohort A (Dabrafenib Monotherapy) 27/78 | Cohort B - Double Combination (Dabrafenib+Trametinib) mBRAF V600E: DAB 150MG BID, TRA 2mG QD 39/57 | Cohort C - Double Combination (Dabrafenib+Trametinib) Naive mBRAF V600E: DAB 150MG BID, TRA 2mG QD 23/36 | Crossover - Double Combination (Dabrafenib+Trametinib): DAB 150MG BID, TRA 2mG QD 4/20 (not_applicable)
Result source: NCT01336634
Results for Non-Small Cell Lung Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Luvometinib | Trametinib |
|---|---|---|
| PFS, median | —Not reported | 2.7 vs 2.6vs DocetaxelNCT013622965 other results
|
| OS, median | —Not reported | 8.1 vs 9.9vs DocetaxelNCT013622964 other results
|
| ORR | —Not reported | —Not reported |
| Duration of response, median | —Not reported | 1.6 vs 2.9vs DocetaxelNCT013622965 other results
|
PFS, median
- Luvometinib
- —Not reported
- Trametinib
- 2.7 vs 2.6vs DocetaxelNCT01362296
5 other results
- 10.2 NCT01336634
- 10.8 NCT01336634
- 5.4 NCT01336634
- 11 NCT01336634
- 13.9 NCT04452877
OS, median
- Luvometinib
- —Not reported
- Trametinib
- 8.1 vs 9.9vs DocetaxelNCT01362296
4 other results
- 18.2 NCT01336634
- 17.3 NCT01336634
- 12.7 NCT01336634
- 25.3 NCT04452877
ORR
- Luvometinib
- —Not reported
- Trametinib
- —Not reported
Duration of response, median
- Luvometinib
- —Not reported
- Trametinib
- 1.6 vs 2.9vs DocetaxelNCT01362296
5 other results
- 9.8 NCT01336634
- 10.2 NCT01336634
- 11.8 NCT01336634
- 14.9 NCT04452877
- 13.4 NCT01336634
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Luvometinib: no structured comparison results are available for Non-Small Cell Lung Cancer.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Luvometinib: 0 of 4 rows · Trametinib: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Trametinib |
|---|---|
| Dropout rate | —2 mga NCT01362296 · Phase 2 show 8 more resultsn/a: no completion milestone2 mg NCT01362296 · Phase 2 16.7%150mg BID NCT01336634 · Phase 2 · monotherapy 14%DAB 150MG BID, TRA 2mG QD NCT01336634 · Phase 2 · combination 25%DAB 150MG BID, TRA 2mG QD NCT01336634 · Phase 2 · combination —DAB 150MG BID, TRA 2mG QD NCT01336634 · Phase 2 · combination 77.5%Dabrafenib in Combination With Tra NCT04452877 · Phase 2 · registry result, not featured evidence · combination —Dabrafenib in Combination With Tra NCT04452877 · Phase 2 · registry result, not featured evidence · combination —Dabrafenib in Combination With Tra NCT04452877 · Phase 2 · registry result, not featured evidence · combination |
| Discontinued due to AEs | —2 mga NCT01362296 · Phase 2 show 8 more results23%2 mg NCT01362296 · Phase 2 —150mg BID NCT01336634 · Phase 2 · monotherapy —DAB 150MG BID, TRA 2mG QD NCT01336634 · Phase 2 · combination —DAB 150MG BID, TRA 2mG QD NCT01336634 · Phase 2 · combination —DAB 150MG BID, TRA 2mG QD NCT01336634 · Phase 2 · combination 12.5%Dabrafenib in Combination With Tra NCT04452877 · Phase 2 · registry result, not featured evidence · combination —Dabrafenib in Combination With Tra NCT04452877 · Phase 2 · registry result, not featured evidence · combination —Dabrafenib in Combination With Tra NCT04452877 · Phase 2 · registry result, not featured evidence · combination |
| Serious AEs | 52.2%2 mga NCT01362296 · Phase 2 show 8 more results36.8%2 mg NCT01362296 · Phase 2 44%150mg BID NCT01336634 · Phase 2 · monotherapy 66.7%DAB 150MG BID, TRA 2mG QD NCT01336634 · Phase 2 · combination 66.7%DAB 150MG BID, TRA 2mG QD NCT01336634 · Phase 2 · combination 45%DAB 150MG BID, TRA 2mG QD NCT01336634 · Phase 2 · combination —Dabrafenib in Combination With Tra NCT04452877 · Phase 2 · registry result, not featured evidence · combination 50%Dabrafenib in Combination With Tra NCT04452877 · Phase 2 · registry result, not featured evidence · combination 6.3%Dabrafenib in Combination With Tra NCT04452877 · Phase 2 · registry result, not featured evidence · combination |
| Most frequent reported AEs | show 7 more resultsDAB 150MG BID, TRA 2mG QD pyrexia 61.1% nausea 58.3% diarrhoea 41.7% NCT01336634 · Phase 2 · combination anaemia 52.5% hypoalbuminaemia 47.5% pyrexia 45% NCT04452877 · Phase 2 · registry result, not featured evidence · combination hypoalbuminaemia 6.3% abdominal discomfort 0% abdominal pain upper 0% NCT04452877 · Phase 2 · registry result, not featured evidence · combination |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Trametinib
show 3 more results
show 4 more results
show 4 more results
show 3 more results
show 1 more result
+ 4 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Luvometinib's landscape · Trametinib's landscape